ELDN vs ELVN

Eledon Pharmaceuticals, Inc. vs Enliven Therapeutics, Inc. — Valuation Comparison 2026

ELDN

Biotechnology
Eledon Pharmaceuticals, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$3.87
Last close
Models
7/13
Active
VS

ELVN

Biotechnology
Enliven Therapeutics, Inc.
Quality
3.8
out of 10
Value Trap
30
LOW
Price
$40.65
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType ELDN Fair ValueELDN Upside ELVN Fair ValueELVN Upside
Bayesian DCF Intrinsic $1.08 -72.1% $13.43 -67.0%
Earnings Power Value Intrinsic $20.47 -53.8%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.11 -97.0% $2.77 -93.4%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ELDN vs ELVN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ELDN vs ELVN — Which Stock Is More Undervalued?

ELDN scores higher with a 3.9/10 quality rating vs ELVN's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Eledon Pharmaceuticals, Inc. (ELDN) and Enliven Therapeutics, Inc. (ELVN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ELDN currently trades at $3.87 with a QOC of 3.9/10, while ELVN trades at $40.65 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).